Progress in developing virus-like particle influenza vaccines. (2nd October 2016)

• Record Type: Journal Article
• Authors: Quan, Fu-Shi; Lee, Young-Tae; Kim, Ki-Hye; Kim, Min-Chul; Kang, Sang-Moo
• Is Part Of: Expert review of vaccines. Volume 15:Number 10(2016)
• Page Start: 1281
• Page End: 1293
• Publication Date: 2016-10-02
• Subjects: Influenza virus -- virus-like particles -- vaccines -- strain-specific protection -- cross protection; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2016.1175942
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.